{"record_key":"rezq-bio-inc","identifier":"rezq-bio-inc","external_key":"761112","title":"Rezq Bio, Inc.","summary":null,"url":"https://inventions.pitt.edu/startups/rezq-bio-inc","json_url":"https://inventions.pitt.edu/startups/rezq-bio-inc.json","object_key":"startups","description":"Rezq Bio is developing therapies designed to restore immune tolerance, beginning with type 1 diabetes. Its lead program uses a patient’s own dendritic cells to address the immune response that attacks healthy tissue. The company is preparing this investigational therapy for Phase 1b/2a development and exploring microsphere-based delivery for broader applications. [1]: https://www.rezq.bio/\nThe Pittsburgh company’s scientific foundation includes University of Pittsburgh diabetes research and co-founder David Finegold’s clinical expertise. Its pipeline also explores localized treatment for inflammatory bowel disease and protection of transplanted cells, with the goal of reducing reliance on broad immune suppression. [2]: https://www.startuphealth.com/startup-health-blog/2023/05/25/introducing-the-type-1-diabetes-moonshot-fellowship-community [1]: https://www.rezq.bio/","attributes":[{"key":"website","label":"Website","values":["https://www.rezq.bio/"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Immunology","Endocrinology and Metabolic Diseases"]},{"key":"funding_stage","label":"Funding Stage","values":["Seed"]},{"key":"founders","label":"Founders","values":["Arjun Hattiangadi","Nick Giannoukakis","Massimo Trucco","David Finegold"]}],"related":[]}